Sanofi to invest €400 million on Singapore vaccine production site
pharmafile | April 12, 2021 | News story | Sales and Marketing | Sanofi, Vaccine
Sanofi have today announced a €400 million investment to create a unique vaccine production centre in Singapore, in partnership with the Singapore Economic Development Board (EDB).
The Singapore site will take five years to build and aims to complement Sanofi’s existing manufacturing capacities in Europe and North America and will become a regional centre for vaccine production in Asia.
The French multinational corporation said the project is expected to create up to 200 local jobs and enable the firm to quickly respond to future pandemic risks.
Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur, said: “As a major healthcare player, it’s our responsibility to act and to meet the unprecedented growing demands for vaccines.
“By investing in a new production site in Singapore, Sanofi is aiming to strengthen production capacity to meet ever-growing global demands on vaccines, and answer more rapidly to future pandemics. We are very pleased by the strong collaboration with the Singapore Economic Development Board to achieve this exciting milestone.”
The new factory will be able to produce three to four vaccines simultaneously, versus only one in current industrial sites. In addition, the factory will have the flexibility to leverage multiple vaccine manufacturing technology platforms based on different cell types.
The project is currently entering its design phase, with construction expected to begin in Q3 2021. The five-year project will see the site fully operational in 2026, once all qualifications and validations of the first manufactured vaccine have been completed.
Dr Beh Swan Gin, Chairman, EDB, said: “Sanofi’s decision to locate its first-in-Asia digitally-enabled vaccine production centre in Singapore, to supply markets in the region and beyond, is an endorsement of Singapore’s position as a leading centre for advanced manufacturing.
“EDB will continue to promote digitalisation, automation and innovation to transform the manufacturing sector and create good jobs for Singaporeans.”
Kat Jenkins
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
